Page last updated: 2024-12-10
azafrin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
azafrin: constituent of Centranthera grandiflora [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Centranthera | genus | [no description available] | Orobanchaceae | The broom-rape plant family of the order Lamiales.[MeSH] |
| Centranthera grandiflora | species | [no description available] | Orobanchaceae | The broom-rape plant family of the order Lamiales.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5281225 |
| CHEBI ID | 2944 |
| SCHEMBL ID | 114812 |
| MeSH ID | M0137351 |
Synonyms (17)
| Synonym |
|---|
| azafrin |
| C08581 |
| 507-61-9 |
| (2e,4e,6e,8e,10e,12e,14e)-15-[(1r,2r)-1,2-dihydroxy-2,6,6-trimethylcyclohexyl]-4,9,13-trimethylpentadeca-2,4,6,8,10,12,14-heptaenoic acid |
| ktc84vde1o , |
| 5,6-dihydro,5,6-dihydroxy-10'-apo-beta,psi-carotenoic acid |
| 10'-apo-beta,psi-carotenoic acid, 5,6-dihydro-5,6-dihydroxy-, (5r,6r)- |
| unii-ktc84vde1o |
| 2,4,6,8,10,12,14-pentadecaheptaenoic acid, 15-((1r,2r)-1,2-dihydroxy-2,6,6-trimethylcyclohexyl)-4,9,13-trimethyl-, (2e,4e,6e,8e,10e,12e,14e)- |
| azafrin [mi] |
| SCHEMBL114812 |
| CHEBI:2944 |
| NYWCITDWPAZNBU-DYISAODMSA-N |
| 10'-apo-.beta.,.psi.-carotenoic acid, 5,6-dihydro-5,6-dihydroxy-, (5r,6r)- |
| c.i. 75110 |
| Q27105895 |
| DTXSID90878674 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| sesterterpenoid | Any terpenoid derived from a sesterterpene. The term includes compounds in which the C25 skeleton of the parent sesterterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). Sometimes sesterterpenoids are erroneously referred to as sesterpenoids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 50.73
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (50.73) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||